Patent application number | Description | Published |
20080214650 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin. | 09-04-2008 |
20080269488 | Novel crystalline forms of gatifloxacin - Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, and methods for their preparation. | 10-30-2008 |
20080319075 | Polymorphic forms of nateglinide - Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration. | 12-25-2008 |
20090012301 | FEXOFENADINE CRYSTAL FORM AND PROCESSES FOR ITS PREPARATION THEREOF - Provided is a crystalline form of fexofenadine free base and processes for its preparation. | 01-08-2009 |
20090030057 | Pharmaceutical composition of telmisartan - The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%. At least one water insoluble diluent is preferred for use in the pharmaceutical composition in an amount from about 40% to about 70% of the total weight of the pharmaceutical composition. A preferred water insoluble diluent is microcrystalline cellulose. Also described are a pharmaceutical composition comprising telmisartan having a powder X-ray diffraction pattern, methods of preparing such pharmaceutical composition, and a crystalline form of Telmisartan. | 01-29-2009 |
20090054486 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE - Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI. | 02-26-2009 |
20090082398 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION - Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation. | 03-26-2009 |
20090149497 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE - The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is anhydrous, but can be crystallized as a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms. | 06-11-2009 |
20100016579 | Crystalline forms of quetiapine hemifumarate - The present invention relates to novel crystalline forms of quetiapine hemifumarate, denominated quetiapine hemifumarate form II and quetiapine hemifumarate form III. These novel crystalline forms of quetiapine hemifumarate have been characterized by methods including x-ray powder diffraction (XRD), Fourier transform IR spectroscopy (FTIR), differential scanning calorimetry (DSC), and thermal gravimetric analysis (TGA). Methods for preparation of the novel crystalline quetiapine hemifumarate form II as its chloroform solvate and its dichloromethane solvate, form III as its chloroform solvate, and form I are provided. | 01-21-2010 |